{"id":1377,"date":"2020-02-10T17:34:36","date_gmt":"2020-02-10T16:34:36","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=1377"},"modified":"2022-07-07T15:32:55","modified_gmt":"2022-07-07T13:32:55","slug":"gyala-therapeutics","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/","title":{"rendered":"Gyala Therapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">Gyala Therapeutics es una empresa <em>spin-off<\/em> fundada por el <strong>Hospital Cl\u00ednic de Barcelona &#8211; IDIBAPS<\/strong>. La compa\u00f1\u00eda se centra en el desarrollo de terapias <strong>CAR-T<\/strong> contra una <strong>nueva<\/strong> diana para las neoplasias hematol\u00f3gicas, como la leucemia mieloide aguda. La compa\u00f1\u00eda aprovecha la experiencia acumulada en el Hospital Cl\u00ednic de Barcelona en el desarrollo y autorizaci\u00f3n del CAR-T ARI-0001 contra CD19.<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO: Claudio Santos<\/li>\r\n<li>Ubicaci\u00f3n: Barcelona<\/li>\r\n<li>P\u00e1gina web: <a href=\"http:\/\/gyalatx.com\" target=\"_blank\" rel=\"noreferrer noopener\">www.gyalatx.com<\/a><\/li>\r\n<\/ul>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[507],"class_list":["post-1377","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-invivoventures"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gyala Therapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gyala Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Gyala Therapeutics es una empresa spin-off fundada por el Hospital Cl\u00ednic de Barcelona &#8211; IDIBAPS. La compa\u00f1\u00eda se centra en el desarrollo de terapias CAR-T contra una nueva diana para las neoplasias hematol\u00f3gicas, como la leucemia mieloide aguda. La compa\u00f1\u00eda aprovecha la experiencia acumulada en el Hospital Cl\u00ednic de Barcelona en el desarrollo y autorizaci\u00f3n\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-07T13:32:55+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/\",\"name\":\"Gyala Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-10T16:34:36+00:00\",\"dateModified\":\"2022-07-07T13:32:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gyala Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gyala Therapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"Gyala Therapeutics - Invivo Partners","og_description":"Gyala Therapeutics es una empresa spin-off fundada por el Hospital Cl\u00ednic de Barcelona &#8211; IDIBAPS. La compa\u00f1\u00eda se centra en el desarrollo de terapias CAR-T contra una nueva diana para las neoplasias hematol\u00f3gicas, como la leucemia mieloide aguda. La compa\u00f1\u00eda aprovecha la experiencia acumulada en el Hospital Cl\u00ednic de Barcelona en el desarrollo y autorizaci\u00f3n","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/","og_site_name":"Invivo Partners","article_modified_time":"2022-07-07T13:32:55+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/","name":"Gyala Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-10T16:34:36+00:00","dateModified":"2022-07-07T13:32:55+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/gyala-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Gyala Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/1377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=1377"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=1377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}